1. ALLA AKTIER
  2. NYHETER
  3. BICO

BICO

Nyheter BICO Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

BICO Publishes Annual Report and Sustainability Report 2022

REG

BICO Group AB (publ) today publishes its annual report and sustainability report for 2022 on its website.

https://bico.com/investors/financials/financial-reports-and-presentations/

The report describes the company’s business model, market, strategy, and roadmap for growth. It includes detailed coverage of our environment, social and governance engagements and commitment to the UN Global Compact.

”I would like to thank our dedicated and passionate team for the tremendous efforts in 2022, the Board for their steady and crucial guidance, our shareholders for their continued confidence in us, and our amazing customers for their loyalty. We look forward to another year with continued improvements and delivering on our profitable growth strategy.”

Erik Gatenholm, President & CEO BICO Group

For further information, please contact:
Åsa Hillsten, Senior Advisor Investor Relations, BICO Group AB
Phone: +46 70-081 81 17
Email: ash@bico.com

About BICO
BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

This information is information that BICO Group is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-03-17 11:00 CET.

Attachments
BICO Annual Report 2022 ENG

Datum 2023-03-17, kl 11:00
Källa MFN
Bifogade filer
BICO Annual Report 2022 ENG